Safety and Efficacy of Platinum Combination Chemotherapy Plus Pembrolizumab vs Platinum Combination Chemotherapy Plus Nivolumab–Ipilimumab for Treatment-Naive Advanced NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial
Lancet Respir Med 2024 Aug 16;[EPub Ahead of Print], Y Shiraishi, S Nomura, S Sugawara, H Horinouchi, Y Yoneshima, H Hayashi, K Azuma, S Hara, S Niho, R Morita, M Yamaguchi, T Yokoyama, K Yoh, T Kurata, H Okamoto, M Okamoto, T Kijima, K Kasahara, Y Fujiwara, S Murakami, S Kanda, H Akamatsu, S Takemoto, H Kaneda, T Kozuki, M Ando, Y Sekino, H Fukuda, Y Ohe, I OkamotoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.